FDA Cleared

We pride ourselves in working with the FDA to ensure safety and reliability for end customers.

Athelas was granted a FDA 510K Class 2 clearance for the Athelas One device. The system is cleared for point-of-care indications in the evaluation of WBC and NEUT%.


Clinically Validated

We take accuracy and transparency seriously. Read our third-party clinical white paper on the accuracy of our capillary WBC and Neutrophil results versus venous blood samples on the Sysmex XE-5000.

Blood: Clinical Third Party Validation of the Athelas Device

View Publication
November 29, 2018

Ann. Clinical Psychiatry - Athelas and Clozapine

View Publication
May 1, 2021

FDA 510K Clearance Studies

View Publication
November 5, 2018

Athelas for Clozapine - Cost Savings Analysis

View Publication
July 28, 2023

Start earning revenue with Athelas today

Practices use Athelas to deliver remote care programs and increase their revenue.

Get a free demo